Samsung Biologics Faces Rising Uncertainty Despite Strong Q1 Outlook Amid Escalating Labor Dispute

Samsung Biologics Faces Rising Uncertainty Despite Strong Q1 Outlook Amid Escalating Labor Dispute: Paul Lee / Published : 04/22/2026 06:35 AM

Photo courtesy of Yonhap News

[Alpha Biz= Paul Lee] Samsung Biologics is expected to post improved earnings for the first quarter of 2026, but escalating labor tensions are emerging as a key risk factor, raising concerns over potential operational disruptions and investor sentiment.

According to financial data providers on April 21, Samsung Biologics’ operating profit for the first quarter is projected to reach around KRW 612 billion, representing an increase of more than 25% year-on-year. Revenue is expected to remain relatively stable at approximately KRW 1.298 trillion.

However, alongside the positive earnings outlook, labor-management conflict is intensifying. The company is scheduled to release its first-quarter earnings on April 22, the same day the union plans to hold a large-scale rally outside the workplace. The union has also announced plans to launch a general strike starting May 1, bringing both strong performance expectations and labor risks into focus simultaneously.

The gap between the two sides remains wide. Between December 23, 2025, and March 13, 2026, management and labor held 13 rounds of negotiations over wages and collective agreements, but failed to reach a consensus. Subsequent mediation efforts also broke down. The union secured 95.52% approval in a strike authorization vote and is demanding a 14% average wage increase, a KRW 30 million bonus per employee, a performance-based payout equivalent to 20% of operating profit, and stock allocations over three years. Management, on the other hand, is reportedly offering a wage increase of around 6.2%.

The company is particularly concerned about potential production disruptions if a strike materializes. In biopharmaceutical manufacturing, interruptions in cultivation and purification processes can lead to the disposal of entire batches, resulting in significant financial losses. Citing these risks, Samsung Biologics filed for an injunction on April 1 with the Incheon District Court to prohibit industrial action by the union.

At the same time, the company is continuing to expand operations, including ramping up its fifth plant and investing in a third bio campus. During its annual earnings announcement in January, Samsung Biologics outlined key investment plans, including the completion of Plant 5 and securing land for its third bio campus. The company reported annual revenue of KRW 4.557 trillion and operating profit of KRW 2.069 trillion for the previous year.

If the union’s demands are applied in full, the financial burden could be substantial. Allocating 20% of last year’s operating profit (KRW 2.069 trillion) toward performance-based bonuses would amount to roughly KRW 413.8 billion. In addition, providing KRW 30 million in incentives to each of the 3,689 union members would require approximately KRW 110.7 billion. However, these figures are rough estimates based on publicly disclosed demands and workforce size, and actual costs may vary depending on final terms.

A court ruling is also expected to be a critical variable. A hearing was held on April 9, and a decision is anticipated soon following further review of submitted materials. The union argues that the company’s injunction request effectively restricts the right to strike, while management maintains that the measure is necessary to ensure continuity of essential operations.

Industry observers note that the dispute could extend beyond a typical labor issue, potentially affecting Samsung Biologics’ competitiveness in securing contracts and maintaining investor confidence. Given the nature of the contract development and manufacturing organization (CDMO) business, where clients prioritize delivery timelines and quality reliability, any disruption could weigh not only on short-term performance but also on long-term credibility.